» Articles » PMID: 31307494

"We Were Afraid of the Lion That Has Roared Next to Us"; Community Response to Reactive Focal Mass Drug Administration for Malaria in Eswatini (formerly Swaziland)

Overview
Journal Malar J
Publisher Biomed Central
Specialty Tropical Medicine
Date 2019 Jul 17
PMID 31307494
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Reactive focal mass drug administration (rfMDA), or presumptive treatment without malaria testing of household members and neighbours of a passively identified malaria case, is currently being explored as a possible malaria elimination strategy in low transmission settings. One of the primary factors determining the effectiveness of rfMDA on reducing or interrupting transmission is achieving high coverage of the target population with drug administration. This study aims to explore the acceptability of rfMDA and identify facilitators and barriers to its potential implementation, as well as the community's general knowledge, attitudes and beliefs with regard to malaria elimination.

Methods: A qualitative study was performed using focus group discussions (FGDs) among villagers that received rfMDA through the National Malaria Control Programme in the low transmission setting of Eswatini as part of a 2-year clinical trial. FGDs were audio-recorded, transcribed and translated into English. All transcripts were managed in Dedoose and underwent qualitative content analysis.

Results: The majority of participants perceived their community to be at high risk of malaria. Witnessing others in their community suffer from malaria, proximity to Mozambique, various ecological factors, and the presence of mosquitoes contributed to this perception. The greatest motivator of participation in rfMDA was witnessing someone else suffer from malaria, since most participants had not personally experienced malaria themselves. Participants valued the education on rfMDA and on malaria in general, particularly when communicated by nurses and other health workers from the Ministry of Health. Participants were overwhelmingly motivated to participate in rfMDA in order to obtain protection from malaria. Most participants did not understand the concept of sub-clinical infection and, therefore, did not perceive the anti-malarial medication given in rfMDA to be a treatment medication.

Conclusions: Perceived risk for malaria was a major driver of acceptability; therefore, future intervention campaigns could aim to better quantify risk to inform interventions and encourage uptake. There were misunderstandings about the asymptomatic reservoir of parasites in humans. Given that this phenomenon is the rationale for rfMDA, this misunderstanding could threaten the uptake of the intervention if it persists in the community. Using local authorities to deliver messaging, additional education on this concept with re-inforcement that risk of malaria is ongoing, even in the absence of frequent cases, may help to maximize and maintain acceptability.

Citing Articles

Understanding psychosocial determinants of malaria behaviours in low-transmission settings: a scoping review.

Casella A, Monroe A, Toso M, Hunter G, Underwood C, Pillai R Malar J. 2024; 23(1):15.

PMID: 38200574 PMC: 10782749. DOI: 10.1186/s12936-023-04831-9.


Assessing the acceptability and feasibility of reactive drug administration for malaria elimination in a Plasmodium vivax predominant setting: a qualitative study in two provinces in Thailand.

Suwannarong K, Cotter C, Ponlap T, Bubpa N, Thammasutti K, Chaiwan J BMC Public Health. 2023; 23(1):1346.

PMID: 37438774 PMC: 10339568. DOI: 10.1186/s12889-023-15852-z.


Acceptability and perceived barriers to reactive focal mass drug administration in the context of a malaria elimination program in Magude district, Southern Mozambique: A qualitative study.

Cuinhane C, Galatas B, Lopez J, Djive H, Nhantumbo H, Murato I PLoS One. 2023; 18(3):e0283160.

PMID: 37000890 PMC: 10065238. DOI: 10.1371/journal.pone.0283160.


Effectiveness and safety of reactive focal mass drug administration (rfMDA) using dihydroartemisinin-piperaquine to reduce malaria transmission in the very low-endemic setting of Eswatini: a pragmatic cluster randomised controlled trial.

Vilakati S, Mngadi N, Benjamin-Chung J, Dlamini N, Kang Dufour M, Whittemore B BMJ Glob Health. 2021; 6(6).

PMID: 34193475 PMC: 8246301. DOI: 10.1136/bmjgh-2021-005021.


Effectiveness and cost-effectiveness of reactive, targeted indoor residual spraying for malaria control in low-transmission settings: a cluster-randomised, non-inferiority trial in South Africa.

Bath D, Cook J, Govere J, Mathebula P, Morris N, Hlongwana K Lancet. 2021; 397(10276):816-827.

PMID: 33640068 PMC: 7910276. DOI: 10.1016/S0140-6736(21)00251-8.


References
1.
De Martin S, von Seidlein L, Deen J, Pinder M, Walraven G, Greenwood B . Community perceptions of a mass administration of an antimalarial drug combination in The Gambia. Trop Med Int Health. 2001; 6(6):442-8. DOI: 10.1046/j.1365-3156.2001.00723.x. View

2.
Okell L, Drakeley C, Bousema T, Whitty C, Ghani A . Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS Med. 2008; 5(11):e226. PMC: 2586356. DOI: 10.1371/journal.pmed.0050226. View

3.
Ishengoma D, Francis F, Mmbando B, Lusingu J, Magistrado P, Alifrangis M . Accuracy of malaria rapid diagnostic tests in community studies and their impact on treatment of malaria in an area with declining malaria burden in north-eastern Tanzania. Malar J. 2011; 10:176. PMC: 3145609. DOI: 10.1186/1475-2875-10-176. View

4.
Kunene S, Phillips A, Gosling R, Kandula D, Novotny J . A national policy for malaria elimination in Swaziland: a first for sub-Saharan Africa. Malar J. 2011; 10:313. PMC: 3219738. DOI: 10.1186/1475-2875-10-313. View

5.
Hsiang M, Hwang J, Kunene S, Drakeley C, Kandula D, Novotny J . Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS One. 2012; 7(1):e29550. PMC: 3253098. DOI: 10.1371/journal.pone.0029550. View